English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/96178
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: Two relevant therapeutic targets for neurological disorders

AuthorsMorales-García, José A. ; Palomo, Valle ; Redondo, Miriam ; Alonso-Gil, Sandra ; Gil, Carmen ; Martínez, Ana ; Pérez Castillo, Ana
Dual GSK-3/PDE7 inhibitors
Issue Date2014
PublisherAmerican Chemical Society
CitationACS Chemical Neuroscience 5(3): 194-204 (2014)
AbstractChronic neuroinflammation has been increasingly recognized as a primary mechanism underlying acute brain injury and neurodegenerative diseases. Enhanced expression of diverse pro-inflammatory agents in glial cells has been shown to contribute to the cell death that takes place in these disorders. Previous data from our group have shown that different inhibitors of the cyclic adenosine monophosphate (cAMP) specific phosphodiesterase 7 (PDE7) and glycogen synthase kinase-3 (GSK-3) enzymes are potent anti-inflammatory agents in different models of brain injury. In this study, we investigated cross-talk between PDE7 and GSK-3, two relevant therapeutic targets for neurological disorders, using a chemical approach. To this end, we compared specific inhibitors of GSK-3 and PDE7 with dual inhibitors of both enzymes with regard to anti-inflammatory effects in primary cultures of glial cells treated with lipopolysaccharide. Our results show that the GSK-3 inhibitors act exclusively by inhibition of this enzyme. By contrast, PDE7 inhibitors exert their effects via inhibition of PDE7 to increase intracellular cAMP levels but also through indirect inhibition of GSK-3. Activation of protein kinase A by cAMP results in phosphorylation of Ser9 of GSK-3 and subsequent inhibition. Our results indicate that the indirect inhibition of GSK-3 by PDE7 inhibitors is an important mechanism that should be considered in the future development of pharmacological treatments. © 2014 American Chemical Society.
Identifiersdoi: 10.1021/cn400166d
issn: 1948-7193
e-issn: 1948-7193
Appears in Collections:(IIBM) Artículos
(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.